Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 and multiple ankyrin repeat domains 2 pseudogene (ENSG00000273858) is a genomic sequence that is highly similar to the functional SHANK2 gene but does not produce a functional protein[2][5][8]. Pseudogenes such as this arise through gene duplication or retrotransposition processes and, by definition, lack protein-coding potential—often due to disabling mutations or incomplete promoter regions. While some pseudogenes have been found to play regulatory roles (e.g., through competing endogenous RNA function), there is no documented evidence that this specific pseudogene has any functional role or therapeutic significance. It is important not to confuse this pseudogene with the functional SHANK2 gene, whose protein product participates in synaptic scaffolding and has been associated with neuropsychiatric conditions. The pseudogene is not a drug target, biomarker, or relevant for therapeutic modulation[2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 and multiple ankyrin repeat domains 2 pseudogene.